You will find all our regulatory press releases in the feed below. Enjoy and share all our other Asarina Pharma news in our regularly updated News Archive.
The following resolutions were passed at the annual general meeting (the “AGM”) of Asarina Pharma AB (publ) (“Asarina Pharma”) on 21 April 2021 in Stockholm. The CEO’s presentation is available at the company’s website.
Full PDFThe shareholders of Asarina Pharma AB (publ), reg. no. 556698-0750, (the “Company”) are hereby summoned to attend the Annual General Meeting (the “AGM”) on 21 April 2021 at 10.00 CEST at Erik Penser Bank, Apelbergsgatan 27 in Stockholm. Registration starts at 09.30 CEST.
Full PDFAsarina Pharma CEO Peter Nordkild: “2020 and early 2021 have seen new research and additional data confirming and consolidating the efficacy and potential of our flagship compound Sepranolone. As we continue forward into an eventful 2021, we remain confident of the significant clinical relevance of Allopregnanolone, and the ability of our flagship compound Sepranolone to…
Full PDFAsarina Pharma CEO Peter Nordkild: “2020 was a turbulent, challenging year for all of us – yet at Asarina Pharma we begin 2021 with continued confidence in the high potential of our flagship compound Sepranolone. We are on schedule to publish our topline results for our Phase IIa Menstrual Migraine study in June 2021, and…
Full PDF(Stockholm, 11 February 2021.) Two sets of new preclinical data presented by Prof Marco Bortolato (Univ. of Utah) confirm that Sepranolone suppresses tics in Tourette Syndrome (TS) and restores Prepulse Inhibition (PPI), a key phenomenon related to TS with no observable side-effects. The new data also point towards the overproduction of Allopregnanolone in acute stress…
Full PDF